Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Herald Grenada.
Press releases published on September 3, 2025
Molecular Assay Market to Grow at a CAGR of 7% During the Forecast Period (2025 – 2030): Wissen Research
GlobeNewswire
·
September 3, 2025
Sheridan, Sept. 03, 2025 (GLOBE NEWSWIRE) -- According to the latest market report published by Wissen Research, the global molecular assay market was valued at USD 16.4 billion in 2024. Furthermore, the market is expected to grow at a CAGR of 7% during …
Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365
GlobeNewswire
·
September 3, 2025
CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization Conference …
DBV Technologies participera à la 27e conférence annuelle H.C. Wainwright Global Investment
GlobeNewswire
·
September 3, 2025
Châtillon, France, le 3 septembre (22:30 CEST) 2025 DBV Technologies participera à la 27e conférence annuelle H.C. Wainwright Global Investment DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP : 23306J309), une …
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
September 3, 2025
SAN FRANCISCO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for …
Pennant Announces Home Health Acquisition in Wyoming
GlobeNewswire
·
September 3, 2025
EAGLE, Idaho, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announced today that effective September 1, 2025, it …
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
GlobeNewswire
·
September 3, 2025
SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that …
Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
GlobeNewswire
·
September 3, 2025
– Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia – – Initial pharmacokinetic (PK) and comparative bioavailability study to initiate in fourth quarter 2025 …
Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
GlobeNewswire
·
September 3, 2025
WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals with weakened immune systems, who are at the highest risk of …
Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority
GlobeNewswire
·
September 3, 2025
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the launch of Sleep Institute, a global clinical insights …
Radiance Biopharma Signs Exclusive License For ‘First In Class’ c-Met/EGFR Targeted Nano Antibody ADC
GlobeNewswire
·
September 3, 2025
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or "Company"), a clinical-stage biotechnology company, announced that it has signed an Exclusive License Agreement with Novatim Immune Therapeutics (Zhejiang) CO., LTD. , (“ …
Longeveron® Announces Key Leadership Updates
GlobeNewswire
·
September 3, 2025
Than Powell, Chief Business Officer and head of business development, appointed Interim CEO Dr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of Directors Wa’el Hashad to step down as CEO and Board member …
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
September 3, 2025
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to …
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
September 3, 2025
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized …
Clover Health CEO Andrew Toy Testifies Before Congress on the Transformative Role of AI in Healthcare, Highlights how Clover is Leading the Way
GlobeNewswire
·
September 3, 2025
WASHINGTON, D.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) – Clover Health CEO Andrew Toy today had the honor to deliver testimony before the U.S. House of …
Banner Health honored for commitment to well-being of physicians
GlobeNewswire
·
September 3, 2025
PHOENIX, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Banner Health has again earned prestigious recognition from American Medical Association (AMA) for the continued commitment to reducing burnout and promoting well-being among health care workers. This marks the …
New Study: Gut Health Program Cuts Infant Eczema Odds by 83% in C-Section Babies
GlobeNewswire
·
September 3, 2025
AUSTIN, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- A new study found that babies born by C-section had 83% lower odds of developing eczema when their families participated in a 6-month gut health support program, compared to those who didn't receive the …
PharmaCorp to Acquire Two Pharmacies in Western Canada
GlobeNewswire
·
September 3, 2025
SASKATOON, Saskatchewan, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that it has entered into definitive share purchase agreements, each dated August 29, 2025 (the “ …
Microbix Hosts Ontario Minister Stephen Crawford
GlobeNewswire
·
September 3, 2025
MISSISSAUGA, Ontario, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces its hosting of the Honourable Stephen Crawford, Ontario’s Minister of …
PDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight
GlobeNewswire
·
September 3, 2025
New York, USA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight The outlook for the PDE4B inhibitors market is changing as this drug class demonstrates significant therapeutic promise in respiratory …
Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
GlobeNewswire
·
September 3, 2025
First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patients Of 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 less …